Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2025 Mar 6;8(1):28.
doi: 10.3390/reports8010028.

A Case Report: The Utility of Multimodality Imaging in the Diagnosis of Cardiac Sarcoidosis-Has It Surpassed the Need for a Biopsy?

Affiliations
Case Reports

A Case Report: The Utility of Multimodality Imaging in the Diagnosis of Cardiac Sarcoidosis-Has It Surpassed the Need for a Biopsy?

Ali Malik et al. Reports (MDPI). .

Abstract

Background and Clinical Significance: Cardiac sarcoidosis (CS) is a rare but life-threatening disorder, occurring in 2-5% of sarcoidosis cases, though post-mortem studies suggest a higher prevalence. It presents diagnostic challenges due to nonspecific symptoms and the low sensitivity of an endomyocardial biopsy. Recent guidelines emphasize multimodal imaging, such as cardiac magnetic resonance imaging (MRI) and positron emission tomography (PET). Given the risk of heart failure (HF) and arrhythmias, early detection is critical. This case highlights the role of non-invasive imaging in diagnosing CS and guiding treatment. Case Presentation: A 54-year-old female with asthma, hyperlipidemia, a recent diagnosis of anterior uveitis, and familial sarcoidosis presented with dyspnea, chest tightness, and worsening cough. Examination revealed anterior uveitis, erythema nodosum, jugular venous distension, and pedal edema. The electrocardiogram (ECG) demonstrated bifascicular block and premature ventricular contractions (PVCs). The brain natriuretic peptide (BNP) was 975 pg/mL, with the transthoracic echocardiogram revealing a left ventricular ejection fraction of 25-30% with global LV akinesis. Coronary computed tomography angiography (CCTA) excluded coronary artery disease. Cardiac MRI showed late gadolinium enhancement, with PET demonstrating active myocardial inflammation, supporting a >90% probability of CS. Given her clinical trajectory and risk of further decompensation, immunosuppressive therapy was initiated without pursuing a biopsy. A dual-chamber implantable cardioverter defibrillator (ICD) was placed due to risk of ventricular arrhythmias. Bronchoalveolar lavage (BAL) showed a CD4/CD8 ratio of 6.53, reinforcing the diagnosis. She responded well to treatment, with symptom improvement and repeat imaging demonstrating signs of disease remission. Conclusions: This case underscores the growing role of multimodal imaging in CS diagnosis, potentially replacing biopsy in select cases. Early imaging-based diagnosis enabled timely immunosuppression and ICD placement, improving outcomes.

Keywords: cardiac sarcoidosis; case report; endomyocardial biopsy; heart failure; multimodality imaging; non-invasive diagnosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 7
Figure 7
Flowchart highlighting our stepwise approach to diagnosing CS in this case.
Figure 1
Figure 1
Eye examination demonstrating anterior uveitis.
Figure 2
Figure 2
Electrocardiogram demonstrating right bundle branch block, left anterior fascicular block, with frequent premature ventricular contractions and a prolonged QT.
Figure 3
Figure 3
Chest X-ray demonstrating cardiomegaly and pulmonary congestion.
Figure 4
Figure 4
Cardiac MRI with multifocal LGE (arrows) consistent with an inflammatory cardiomyopathy.
Figure 5
Figure 5
PET demonstrating multi-focal FDG uptake (arrows) with associated matched perfusion abnormalities in the basal and mid-inferior and inferoseptal segments, basal anterior, basal to mid-anterolateral segments, and apical lateral and inferior segments.
Figure 6
Figure 6
FDG PET-CT showing myocardial FDG uptake (arrows).

Similar articles

References

    1. Birnie D.H., Kandolin R., Nery P.B., Kupari M. Cardiac manifestations of sarcoidosis: Diagnosis and management. Eur. Heart J. 2017;38:2663–2670. doi: 10.1093/eurheartj/ehw328. - DOI - PubMed
    1. Terasaki F., Kusano K., Nakajima T., Yazaki Y., Morimoto S.-I., Culver D.A., Isobe M. The characteristics of Japanese guidelines on diagnosis and treatment of cardiac sarcoidosis compared with the previous guidelines. Sarcoidosis Vasc. Diffuse Lung Dis. 2022;39:e2022028. doi: 10.36141/svdld.v39i3.12531. - DOI - PMC - PubMed
    1. Ueberham L., Hagendorff A., Klingel K., Paetsch I., Jahnke C., Kluge T., Ebbinghaus H., Hindricks G., Laufs U., Dinov B. Pathophysiological Gaps, Diagnostic Challenges, and Uncertainties in Cardiac Sarcoidosis. J. Am. Heart Assoc. 2023;12:e027971. doi: 10.1161/JAHA.122.027971. - DOI - PMC - PubMed
    1. Munoz C., Schneider A., Botnar R.M., Prieto C. Recent advances in PET-MRI for cardiac sarcoidosis. Front. Nucl. Med. 2022;2:1032444. doi: 10.3389/fnume.2022.1032444. - DOI - PMC - PubMed
    1. Hussain K., Shetty M. StatPearls [Internet] StatPearls Publishing; Treasure Island, FL, USA: 2024. Cardiac Sarcoidosis. - PubMed

Publication types

LinkOut - more resources